Organovo Stock Price, News & Analysis (NASDAQ:ONVO)

$1.07 -0.02 (-1.83 %)
(As of 02/21/2018 03:54 PM ET)
Previous Close$1.07
Today's Range$1.05 - $1.11
52-Week Range$0.93 - $3.26
Volume910,100 shs
Average Volume1.19 million shs
Market Capitalization$120.81 million
P/E Ratio-2.93
Dividend YieldN/A
Beta2.61

About Organovo (NASDAQ:ONVO)

Organovo logoOrganovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio11.72%
Quick Ratio11.58%

Price-To-Earnings

Trailing P/E Ratio-2.93055555555556
Forward P/E Ratio-3.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.23 million
Price / Sales28.04
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book2.43

Profitability

Trailing EPS($0.36)
Net Income$-38,440,000.00
Net Margins-881.93%
Return on Equity-69.03%
Return on Assets-63.00%

Miscellaneous

Employees113
Outstanding Shares110,840,000

Organovo (NASDAQ:ONVO) Frequently Asked Questions

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

How were Organovo's earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) issued its quarterly earnings results on Thursday, February, 8th. The medical research company reported ($0.07) EPS for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.02. The medical research company had revenue of $1.15 million for the quarter, compared to analyst estimates of $1.25 million. Organovo had a negative return on equity of 69.03% and a negative net margin of 881.93%. Organovo's quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the company posted ($0.09) earnings per share. View Organovo's Earnings History.

Where is Organovo's stock going? Where will Organovo's stock price be in 2018?

5 equities research analysts have issued 12 month target prices for Organovo's stock. Their forecasts range from $3.00 to $5.00. On average, they expect Organovo's share price to reach $3.94 in the next twelve months. View Analyst Ratings for Organovo.

What are Wall Street analysts saying about Organovo stock?

Here are some recent quotes from research analysts about Organovo stock:

  • 1. According to Zacks Investment Research, "Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California. " (2/17/2018)
  • 2. BTIG Research analysts commented, "Reset Delays Ramp; Trimming PT From $5 to $3 We are updating our model and price target to reflect Q3 results and a slower than anticipated revenue ramp as a result of the company’s strategy focus toward fast-growing, higher margin compound screening and disease modeling. We continue to feel ONVO is a long-term investment with sizable market opportunities ($3B+) but as the technology is quite new, predicting the rate at which pharma and research partners will adopt this new technology can be tricky. As our model now incorporates more risk in the near-term given the change in strategy, our revised DCF yields a $3 PT, down from $5 previously. We maintain our Buy rating.   Commentary on revenue mix is encouraging. In the call, management noted a 60%/40% split between repeat and new orders in the first half of the fiscal year, consistent with the mix seen in Fiscal 2017. Additionally, average revenue per order also continues to rise, driven by the aforementioned shift to higher value disease modeling. Finally, management also suggested the potential for a few of its clients to shift from single project to annual revenue commitment contracts over the next couple of quarters.   Valuation: Our price target is $3, based on a DCF analysis that assumes a WACC of 15% and a LT growth rate of 3%. Risks follow on page 6." (11/16/2017)

Who are some of Organovo's key competitors?

Who are Organovo's key executives?

Organovo's management team includes the folowing people:

  • Taylor J. Crouch, President, Chief Executive Officer (Age 57)
  • Sharon Collins Presnell Ph.D., Chief Scientific Officer (Age 47)
  • Jennifer Kinsbruner Bush, Compliance Officer, General Counsel, Corporate Secretary (Age 41)
  • Paul Gallant, General Manager (Age 51)
  • Richard Maroun, Director
  • Robert F Baltera Jr., Lead Independent Director (Age 51)
  • James T. Glover, Independent Director (Age 66)
  • Richard A. Heyman Ph.D., Independent Director (Age 59)
  • Tamar D. Howson, Independent Director (Age 69)

Who owns Organovo stock?

Organovo's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.73%), ARK Investment Management LLC (5.32%), Geode Capital Management LLC (0.86%), Bank of New York Mellon Corp (0.63%), Deutsche Bank AG (0.23%) and TIAA CREF Investment Management LLC (0.21%). Company insiders that own Organovo stock include Eric David and Keith Murphy. View Institutional Ownership Trends for Organovo.

Who sold Organovo stock? Who is selling Organovo stock?

Organovo's stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., TIAA CREF Investment Management LLC, Wells Fargo & Company MN, Teachers Advisors LLC, Deutsche Bank AG and Geode Capital Management LLC. View Insider Buying and Selling for Organovo.

Who bought Organovo stock? Who is buying Organovo stock?

Organovo's stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Bank of New York Mellon Corp, Anson Funds Management LP, Millennium Management LLC and Paloma Partners Management Co. View Insider Buying and Selling for Organovo.

How do I buy Organovo stock?

Shares of Organovo can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Organovo's stock price today?

One share of Organovo stock can currently be purchased for approximately $1.07.

How big of a company is Organovo?

Organovo has a market capitalization of $120.81 million and generates $4.23 million in revenue each year. The medical research company earns $-38,440,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Organovo employs 113 workers across the globe.

How can I contact Organovo?

Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]


MarketBeat Community Rating for Organovo (ONVO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Organovo (NASDAQ:ONVO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.603.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.94$3.94$3.94$6.94
Price Target Upside: 183.27% upside183.27% upside183.27% upside195.21% upside

Organovo (NASDAQ:ONVO) Consensus Price Target History

Price Target History for Organovo (NASDAQ:ONVO)

Organovo (NASDAQ:ONVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017BTIG ResearchReiterated RatingBuy$3.00N/AView Rating Details
11/10/2017CitigroupDowngradeMarket PerformN/AView Rating Details
11/10/2017Raymond James FinancialDowngradeOutperform -> Market Perform$5.00N/AView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$4.00HighView Rating Details
6/12/2017Evercore ISILower Price TargetOutperform$4.00 -> $3.75N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Organovo (NASDAQ:ONVO) Earnings History and Estimates Chart

Earnings by Quarter for Organovo (NASDAQ:ONVO)

Organovo (NASDAQ ONVO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2018Q3 2018($0.09)($0.07)$1.25 million$1.15 millionViewListenView Earnings Details
11/9/2017Q2 2018($0.10)($0.09)$1.38 million$1.36 millionViewN/AView Earnings Details
8/9/2017Q1 2018($0.10)($0.10)$0.92 million$0.99 millionViewListenView Earnings Details
6/7/2017Q4 2017($0.11)($0.10)$0.76 million$0.80 millionViewListenView Earnings Details
2/9/2017Q3 2017($0.10)($0.09)$1.40 million$1.15 millionViewListenView Earnings Details
11/3/2016Q217($0.11)($0.10)$0.50 million$1.38 millionViewListenView Earnings Details
8/4/2016Q1($0.10)($0.09)$0.30 million$0.89 millionViewListenView Earnings Details
6/9/2016Q4($0.11)($0.09)$0.10 million$0.55 millionViewListenView Earnings Details
2/8/2016Q3 2016($0.11)($0.11)ViewN/AView Earnings Details
11/9/2015Q2 2016($0.10)($0.12)ViewN/AView Earnings Details
8/10/2015Q1 2016($0.10)($0.10)ViewN/AView Earnings Details
2/9/2015Q3 2015($0.09)ViewN/AView Earnings Details
11/10/2014Q2 2015($0.11)ViewN/AView Earnings Details
8/12/2014Q1 2015($0.08)ViewN/AView Earnings Details
6/12/2014Q4 2014($0.11)ViewN/AView Earnings Details
2/7/2014Q3 2014($0.06)ViewN/AView Earnings Details
11/12/2013Q2 2014($0.14)ViewN/AView Earnings Details
8/12/2013Q1 2014($0.06)($0.06)ViewN/AView Earnings Details
5/28/2013Q4 2013($0.13)ViewN/AView Earnings Details
3/18/2013Q3 2013($0.05)($0.08)ViewN/AView Earnings Details
11/16/2012Q2 2013$0.70$0.69ViewN/AView Earnings Details
8/15/2012Q1 2013($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Organovo (NASDAQ:ONVO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.17)
2019 EPS Consensus Estimate: ($0.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20181($0.10)($0.10)($0.10)
Q4 20181($0.07)($0.07)($0.07)
Q1 20191($0.09)($0.09)($0.09)
Q2 20191($0.09)($0.09)($0.09)
Q3 20191($0.07)($0.07)($0.07)
Q4 20191($0.07)($0.07)($0.07)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Organovo (NASDAQ:ONVO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Organovo (NASDAQ ONVO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.20%
Institutional Ownership Percentage: 27.29%
Insider Trades by Quarter for Organovo (NASDAQ:ONVO)
Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Organovo (NASDAQ ONVO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2017Keith MurphyCEOSell25,000$3.68$92,000.00View SEC Filing  
1/24/2017Keith MurphyCEOSell25,000$3.51$87,750.006,059,015View SEC Filing  
12/14/2016Keith MurphyCEOSell50,000$3.72$186,000.00View SEC Filing  
8/5/2016Eric DavidEVPSell20,000$4.55$91,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Organovo (NASDAQ ONVO) News Headlines

Source:
DateHeadline
Organovo (ONVO) Lowered to Hold at Zacks Investment ResearchOrganovo (ONVO) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 17 at 6:24 AM
Organovo (ONVO) Stock Rating Upgraded by Zacks Investment ResearchOrganovo (ONVO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 16 at 6:46 AM
Jefferies Group Weighs in on Organovo Holdings Incs FY2018 Earnings (ONVO)Jefferies Group Weighs in on Organovo Holdings Inc's FY2018 Earnings (ONVO)
www.americanbankingnews.com - February 15 at 11:20 AM
Early Breakthroughs Indicate 2018 Will be a Strong Year for 3D TechEarly Breakthroughs Indicate 2018 Will be a Strong Year for 3D Tech
www.prnewswire.com - February 14 at 9:34 AM
Organovo Holdings Inc (ONVO) Given Average Recommendation of "Hold" by BrokeragesOrganovo Holdings Inc (ONVO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 10 at 1:48 AM
Organovo (ONVO) Releases Quarterly  Earnings Results, Beats Expectations By $0.02 EPSOrganovo (ONVO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - February 9 at 12:23 PM
Organovo Announces Fiscal Third-Quarter 2018 Results; Company Updates Full-Year Fiscal 2018 OutlookOrganovo Announces Fiscal Third-Quarter 2018 Results; Company Updates Full-Year Fiscal 2018 Outlook
finance.yahoo.com - February 9 at 9:33 AM
Organovo Holdings Inc (ONVO) Expected to Post Quarterly Sales of $1.23 MillionOrganovo Holdings Inc (ONVO) Expected to Post Quarterly Sales of $1.23 Million
www.americanbankingnews.com - February 9 at 2:50 AM
A Preview Of Organovos Q3 EarningsA Preview Of Organovo's Q3 Earnings
finance.yahoo.com - February 8 at 3:40 PM
Organovo Holdings, Inc. to Host Earnings CallOrganovo Holdings, Inc. to Host Earnings Call
finance.yahoo.com - February 8 at 3:40 PM
 Analysts Anticipate Organovo Holdings Inc (ONVO) to Announce -$0.10 EPS Analysts Anticipate Organovo Holdings Inc (ONVO) to Announce -$0.10 EPS
www.americanbankingnews.com - February 7 at 1:35 PM
Organovo (ONVO) Set to Announce Earnings on WednesdayOrganovo (ONVO) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - January 31 at 2:48 AM
Organovo Announces Release Date for Fiscal Third-Quarter 2018 Financial ResultsOrganovo Announces Release Date for Fiscal Third-Quarter 2018 Financial Results
finance.yahoo.com - January 26 at 8:59 AM
Zacks: Brokerages Anticipate Organovo Holdings Inc (ONVO) Will Announce Quarterly Sales of $1.23 MillionZacks: Brokerages Anticipate Organovo Holdings Inc (ONVO) Will Announce Quarterly Sales of $1.23 Million
www.americanbankingnews.com - January 23 at 6:26 AM
Organovo Holdings Inc (ONVO) Receives Consensus Rating of "Hold" from BrokeragesOrganovo Holdings Inc (ONVO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 16 at 1:38 AM
Organovo (ONVO) Stock Rating Lowered by Zacks Investment ResearchOrganovo (ONVO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - December 28 at 11:42 PM
ETFs with exposure to Organovo Holdings, Inc. : December 28, 2017ETFs with exposure to Organovo Holdings, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 12:54 PM
Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q2, 2018 By the Numbers : December 27, 2017Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q2, 2018 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:06 PM
Organovo (ONVO) Granted Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin DeficiencyOrganovo (ONVO) Granted Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency
www.streetinsider.com - December 26 at 10:11 AM
32 Stocks Moving In Tuesdays Pre-Market Session32 Stocks Moving In Tuesday's Pre-Market Session
feeds.benzinga.com - December 26 at 9:30 AM
Organovo Holdings Inc (ONVO) Receives Consensus Recommendation of "Hold" from AnalystsOrganovo Holdings Inc (ONVO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 22 at 2:06 AM
$1.23 Million in Sales Expected for Organovo Holdings Inc (ONVO) This Quarter$1.23 Million in Sales Expected for Organovo Holdings Inc (ONVO) This Quarter
www.americanbankingnews.com - December 21 at 10:54 AM
Zacks: Brokerages Expect Organovo Holdings Inc (ONVO) Will Announce Earnings of -$0.10 Per ShareZacks: Brokerages Expect Organovo Holdings Inc (ONVO) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - December 19 at 5:20 AM
ETFs with exposure to Organovo Holdings, Inc. : December 15, 2017ETFs with exposure to Organovo Holdings, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 4:47 PM
Where Will Organovo Holdings, Inc. Be in 5 Years?Where Will Organovo Holdings, Inc. Be in 5 Years?
www.fool.com - December 3 at 3:03 PM
Organovo Holdings, Inc. (ONVO) Given Average Recommendation of "Hold" by BrokeragesOrganovo Holdings, Inc. (ONVO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:06 AM
Zacks: Organovo Holdings, Inc. (ONVO) Receives Average Recommendation of "Buy" from BrokeragesZacks: Organovo Holdings, Inc. (ONVO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 19 at 1:16 PM
Organovo Holdings, Inc. (ONVO) Given "Buy" Rating at BTIG ResearchOrganovo Holdings, Inc. (ONVO) Given "Buy" Rating at BTIG Research
www.americanbankingnews.com - November 16 at 10:40 AM
Contrasting Organovo Holdings (ONVO) & Novelion Therapeutics (NVLN)Contrasting Organovo Holdings (ONVO) & Novelion Therapeutics (NVLN)
www.americanbankingnews.com - November 16 at 8:37 AM
 Organovo Holdings, Inc. (ONVO) Given $3.25 Consensus Target Price by Brokerages Organovo Holdings, Inc. (ONVO) Given $3.25 Consensus Target Price by Brokerages
www.americanbankingnews.com - November 15 at 5:06 AM
Zacks: Analysts Expect Organovo Holdings, Inc. (ONVO) Will Announce Quarterly Sales of $1.93 MillionZacks: Analysts Expect Organovo Holdings, Inc. (ONVO) Will Announce Quarterly Sales of $1.93 Million
www.americanbankingnews.com - November 14 at 6:04 AM
Organovo Holdings, Inc. (ONVO) Expected to Post Earnings of -$0.09 Per ShareOrganovo Holdings, Inc. (ONVO) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - November 12 at 5:42 PM
Organovo Holdings, Inc. (ONVO) Rating Lowered to Market Perform at Raymond James Financial, Inc.Organovo Holdings, Inc. (ONVO) Rating Lowered to Market Perform at Raymond James Financial, Inc.
www.americanbankingnews.com - November 12 at 11:16 AM
Citigroup Inc. Downgrades Organovo Holdings, Inc. (ONVO) to Market PerformCitigroup Inc. Downgrades Organovo Holdings, Inc. (ONVO) to Market Perform
www.americanbankingnews.com - November 10 at 2:48 PM
Organovo Holdings, Inc. (ONVO) Releases  Earnings Results, Beats Estimates By $0.01 EPSOrganovo Holdings, Inc. (ONVO) Releases Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - November 9 at 10:36 PM
Head-To-Head Comparison: Organovo Holdings (ONVO) and The CompetitionHead-To-Head Comparison: Organovo Holdings (ONVO) and The Competition
www.americanbankingnews.com - November 6 at 1:20 AM
Organovo Holdings (ONVO) vs. Its Rivals Head to Head ReviewOrganovo Holdings (ONVO) vs. Its Rivals Head to Head Review
www.americanbankingnews.com - November 5 at 1:20 PM
Organovo Holdings, Inc. (ONVO) Receives Consensus Recommendation of "Hold" from AnalystsOrganovo Holdings, Inc. (ONVO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 2 at 12:00 PM
Organovo Holdings, Inc. (ONVO) Set to Announce Earnings on ThursdayOrganovo Holdings, Inc. (ONVO) Set to Announce Earnings on Thursday
www.americanbankingnews.com - November 2 at 3:04 AM
ETFs with exposure to Organovo Holdings, Inc. : October 30, 2017ETFs with exposure to Organovo Holdings, Inc. : October 30, 2017
finance.yahoo.com - October 31 at 7:29 AM
Organovo (ONVO) Reports New Preclinical Data on 3D Bioprinted ... - StreetInsider.comOrganovo (ONVO) Reports New Preclinical Data on 3D Bioprinted ... - StreetInsider.com
www.streetinsider.com - October 21 at 7:29 AM
Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting® 2017 (AASLD)Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting® 2017 (AASLD)
finance.yahoo.com - October 21 at 7:29 AM
ETFs with exposure to Organovo Holdings, Inc. : October 20, 2017ETFs with exposure to Organovo Holdings, Inc. : October 20, 2017
finance.yahoo.com - October 21 at 7:29 AM
Organovo Announces Release Date for Fiscal Second-Quarter 2018 Financial ResultsOrganovo Announces Release Date for Fiscal Second-Quarter 2018 Financial Results
finance.yahoo.com - October 20 at 7:08 AM
Organovo Holdings, Inc. (ONVO) Stock Rating Upgraded by Zacks Investment ResearchOrganovo Holdings, Inc. (ONVO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 15 at 11:32 PM
Critical Review: Organovo Holdings (ONVO) & Its RivalsCritical Review: Organovo Holdings (ONVO) & Its Rivals
www.americanbankingnews.com - October 13 at 2:20 PM
ETFs with exposure to Organovo Holdings, Inc. : October 9, 2017ETFs with exposure to Organovo Holdings, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 8:48 PM
Q3 2018 EPS Estimates for Organovo Holdings, Inc. Decreased by Analyst (ONVO)Q3 2018 EPS Estimates for Organovo Holdings, Inc. Decreased by Analyst (ONVO)
www.americanbankingnews.com - October 9 at 5:56 AM
Organovo Holdings, Inc. (ONVO) Given Average Rating of "Hold" by BrokeragesOrganovo Holdings, Inc. (ONVO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 8 at 9:00 AM
Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q1, 2018 By the Numbers : October 6, 2017Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q1, 2018 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 9:11 AM

SEC Filings

Organovo (NASDAQ:ONVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Organovo (NASDAQ ONVO) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.